Production of alpha 1,3-galactosyltransferase-knockout cloned pigs expressing human alpha 1,2-fucosylosyltransferase.
The production of genetically engineered pigs as xenotransplant donors aims to solve the severe shortage of organs for transplantation in humans. The first barrier to successful xenotransplantation is hyperacute rejection (HAR). HAR is a rapid and massive humoral immune response directed against the pig carbohydrate Galalpha 1,3-Gal epitope, which is synthesized by alpha 1,3-galactosyltransferase (alpha1,3-GT). The Galalpha 1,3-Gal antigen also contributes to subsequent acute vascular rejection events. Genetic modifications of donor pigs transgenic for human complement regulatory proteins or different glycosyltransferases to downregulate Galalpha 1,3-Gal expression have been shown to significantly delay xenograft rejection. However, the complete removal of the Galalpha 1,3-Gal antigen is the most attractive option. In this study, the 5' end of the alpha 1,3-GT gene was efficiently targeted with a nonisogenic DNA construct containing predominantly intron sequences and a Kozak translation initiation site to initiate translation of the neomycin resistance reporter gene. We developed two novel polymerase chain reaction screening methods to detect and confirm the targeted G418-resistant clones. This is the first study to use Southern blot analysis to demonstrate the disruption of the alpha 1,3-GT gene in somatic HT-transgenic pig cells before they were used for nuclear transfer. Transgenic male pigs were produced that possess an alpha 1,3-GT knockout allele and express a randomly inserted human alpha 1,2-fucosylosyltransferase (HT) transgene. The generation of homozygous alpha 1,3-GT knockout pigs with the HT-transgenic background is underway and will be unique. This approach intends to combine the alpha 1,3-GT knockout genotype with a ubiquitously expressed fucosyltransferase transgene producing the universally tolerated H antigen. This approach may prove to be more effective than the null phenotype alone in overcoming HAR and delayed xenograft rejection.
Ramsoondar
Jagdeece J
JJ
Alexion Pharmaceuticals, Inc., Cheshire, Connecticut 06410, USA. jag@columbusfarming.com
Macháty
Zoltán
Z
Costa
Cristina
C
Williams
Barry L
BL
Fodor
William L
WL
Bondioli
Kenneth R
KR
D000818:Animals; D000900:Anti-Bacterial Agents / Q000494:pharmacology; D015139:Blotting, Southern; D002467:Cell Nucleus / Q000187:drug effects / Q000235:genetics; D002478:Cells, Cultured; D019976:Cloning, Organism; D003062:Codon / Q000235:genetics; D017931:DNA Primers; D005091:Exons / Q000235:genetics; D005260:Female; D005333:Fetus / Q000166:cytology; D005347:Fibroblasts; D005434:Flow Cytometry; D005647:Fucosyltransferases / Q000235:genetics*; D005700:Galactosyltransferases / Q000235:genetics*; D006801:Humans; D007438:Introns / Q000235:genetics; D008297:Male; D009355:Neomycin / Q000494:pharmacology; D009865:Oocytes / Q000502:physiology; D011247:Pregnancy; D020133:Reverse Transcriptase Polymerase Chain Reaction; D013552:Swine; D014162:Transfection
D000900:Anti-Bacterial Agents; D003062:Codon; D017931:DNA Primers; D005647:Fucosyltransferases; D005700:Galactosyltransferases; D009355:Neomycin